Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300
PurposeThis study represents a descriptive analysis of preliminary results of a Phase II trial on a novel mixed beam radiotherapy (RT) approach, consisting of carbon ions RT (CIRT) followed by intensity-modulated photon RT, in combination with hormonal therapy, for high-risk prostate cancer (HR PCa)...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.778729/full |
| _version_ | 1819038625639170048 |
|---|---|
| author | Giulia Marvaso Giulia Marvaso Barbara Vischioni Matteo Pepa Mattia Zaffaroni Stefania Volpe Stefania Volpe Filippo Patti Filippo Patti Federica Bellerba Sara Gandini Stefania Comi Giulia Corrao Giulia Corrao Dario Zerini Matteo Augugliaro Cristiana Fodor Stefania Russo Silvia Molinelli Mario Ciocca Rosalinda Ricotti Francesca Valvo Tommaso Giandini Barbara Avuzzi Riccardo Valdagni Riccardo Valdagni Ottavio De Cobelli Ottavio De Cobelli Federica Cattani Ester Orlandi Barbara Alicja Jereczek-Fossa Barbara Alicja Jereczek-Fossa Roberto Orecchia |
| author_facet | Giulia Marvaso Giulia Marvaso Barbara Vischioni Matteo Pepa Mattia Zaffaroni Stefania Volpe Stefania Volpe Filippo Patti Filippo Patti Federica Bellerba Sara Gandini Stefania Comi Giulia Corrao Giulia Corrao Dario Zerini Matteo Augugliaro Cristiana Fodor Stefania Russo Silvia Molinelli Mario Ciocca Rosalinda Ricotti Francesca Valvo Tommaso Giandini Barbara Avuzzi Riccardo Valdagni Riccardo Valdagni Ottavio De Cobelli Ottavio De Cobelli Federica Cattani Ester Orlandi Barbara Alicja Jereczek-Fossa Barbara Alicja Jereczek-Fossa Roberto Orecchia |
| author_sort | Giulia Marvaso |
| collection | DOAJ |
| description | PurposeThis study represents a descriptive analysis of preliminary results of a Phase II trial on a novel mixed beam radiotherapy (RT) approach, consisting of carbon ions RT (CIRT) followed by intensity-modulated photon RT, in combination with hormonal therapy, for high-risk prostate cancer (HR PCa) with a special focus on acute toxicity.MethodsPrimary endpoint was the evaluation of safety in terms of acute toxicity. Secondary endpoints were early and long-term tolerability of treatment, quality of life (QoL), and efficacy. Data on acute and late toxicities were collected according to RTOG/EORTC. QoL of enrolled patients was assessed by IPSS, EORTC QLQ-C30, EORTC QLQ-PR25, and sexual activity by IIEF-5.ResultsTwenty-six patients were enrolled in the study, but only 15 completed so far the RT course and were included. Immediately after CIRT, no patients experienced GI/GU toxicity. At 1 and 3 months from the whole course RT completion, no GI/GU toxicities greater than grade 2 were observed. QoL scores were overall satisfactory.ConclusionsThe feasibility of the proposed mixed treatment schedule was assessed, and an excellent acute toxicity profile was recorded. Such findings instil confidence in the continuation of this mixed approach, with evaluation of long-term tolerability and efficacy. |
| first_indexed | 2024-12-21T08:40:17Z |
| format | Article |
| id | doaj.art-fe76b859e37540c1ac9f11af84dce1fc |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-21T08:40:17Z |
| publishDate | 2021-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-fe76b859e37540c1ac9f11af84dce1fc2022-12-21T19:09:58ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-11-011110.3389/fonc.2021.778729778729Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300Giulia Marvaso0Giulia Marvaso1Barbara Vischioni2Matteo Pepa3Mattia Zaffaroni4Stefania Volpe5Stefania Volpe6Filippo Patti7Filippo Patti8Federica Bellerba9Sara Gandini10Stefania Comi11Giulia Corrao12Giulia Corrao13Dario Zerini14Matteo Augugliaro15Cristiana Fodor16Stefania Russo17Silvia Molinelli18Mario Ciocca19Rosalinda Ricotti20Francesca Valvo21Tommaso Giandini22Barbara Avuzzi23Riccardo Valdagni24Riccardo Valdagni25Ottavio De Cobelli26Ottavio De Cobelli27Federica Cattani28Ester Orlandi29Barbara Alicja Jereczek-Fossa30Barbara Alicja Jereczek-Fossa31Roberto Orecchia32Division of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, ItalyClinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, ItalyDivision of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyDivision of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyDivision of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, ItalyDivision of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyClinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, ItalyDepartment of Experimental Oncology, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyDepartment of Experimental Oncology, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyMedical Physics Unit, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyDivision of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, ItalyDivision of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyDivision of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyDivision of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyClinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, ItalyClinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, ItalyClinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, ItalyClinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, ItalyClinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, ItalyMedical Physics Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, ItalyDepartment of Radiation Oncology 1, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, ItalyDepartment of Radiation Oncology 1, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, ItalyDivision of Urology, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyMedical Physics Unit, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyClinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, ItalyDivision of Radiotherapy, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, ItalyScientific Directorate, Istituto Europeo di Oncologia (IEO), European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, ItalyPurposeThis study represents a descriptive analysis of preliminary results of a Phase II trial on a novel mixed beam radiotherapy (RT) approach, consisting of carbon ions RT (CIRT) followed by intensity-modulated photon RT, in combination with hormonal therapy, for high-risk prostate cancer (HR PCa) with a special focus on acute toxicity.MethodsPrimary endpoint was the evaluation of safety in terms of acute toxicity. Secondary endpoints were early and long-term tolerability of treatment, quality of life (QoL), and efficacy. Data on acute and late toxicities were collected according to RTOG/EORTC. QoL of enrolled patients was assessed by IPSS, EORTC QLQ-C30, EORTC QLQ-PR25, and sexual activity by IIEF-5.ResultsTwenty-six patients were enrolled in the study, but only 15 completed so far the RT course and were included. Immediately after CIRT, no patients experienced GI/GU toxicity. At 1 and 3 months from the whole course RT completion, no GI/GU toxicities greater than grade 2 were observed. QoL scores were overall satisfactory.ConclusionsThe feasibility of the proposed mixed treatment schedule was assessed, and an excellent acute toxicity profile was recorded. Such findings instil confidence in the continuation of this mixed approach, with evaluation of long-term tolerability and efficacy.https://www.frontiersin.org/articles/10.3389/fonc.2021.778729/fullcarbon-ion radiotherapyintensity modulated radiotherapyhigh-risk prostate cancerphase II studymixed-beam approach |
| spellingShingle | Giulia Marvaso Giulia Marvaso Barbara Vischioni Matteo Pepa Mattia Zaffaroni Stefania Volpe Stefania Volpe Filippo Patti Filippo Patti Federica Bellerba Sara Gandini Stefania Comi Giulia Corrao Giulia Corrao Dario Zerini Matteo Augugliaro Cristiana Fodor Stefania Russo Silvia Molinelli Mario Ciocca Rosalinda Ricotti Francesca Valvo Tommaso Giandini Barbara Avuzzi Riccardo Valdagni Riccardo Valdagni Ottavio De Cobelli Ottavio De Cobelli Federica Cattani Ester Orlandi Barbara Alicja Jereczek-Fossa Barbara Alicja Jereczek-Fossa Roberto Orecchia Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300 Frontiers in Oncology carbon-ion radiotherapy intensity modulated radiotherapy high-risk prostate cancer phase II study mixed-beam approach |
| title | Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300 |
| title_full | Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300 |
| title_fullStr | Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300 |
| title_full_unstemmed | Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300 |
| title_short | Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300 |
| title_sort | mixed beam approach for high risk prostate cancer carbon ion boost followed by photon intensity modulated radiotherapy preliminary results of phase ii trial airc ig 14300 |
| topic | carbon-ion radiotherapy intensity modulated radiotherapy high-risk prostate cancer phase II study mixed-beam approach |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.778729/full |
| work_keys_str_mv | AT giuliamarvaso mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT giuliamarvaso mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT barbaravischioni mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT matteopepa mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT mattiazaffaroni mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT stefaniavolpe mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT stefaniavolpe mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT filippopatti mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT filippopatti mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT federicabellerba mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT saragandini mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT stefaniacomi mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT giuliacorrao mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT giuliacorrao mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT dariozerini mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT matteoaugugliaro mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT cristianafodor mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT stefaniarusso mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT silviamolinelli mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT mariociocca mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT rosalindaricotti mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT francescavalvo mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT tommasogiandini mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT barbaraavuzzi mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT riccardovaldagni mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT riccardovaldagni mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT ottaviodecobelli mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT ottaviodecobelli mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT federicacattani mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT esterorlandi mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT barbaraalicjajereczekfossa mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT barbaraalicjajereczekfossa mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 AT robertoorecchia mixedbeamapproachforhighriskprostatecancercarbonionboostfollowedbyphotonintensitymodulatedradiotherapypreliminaryresultsofphaseiitrialaircig14300 |